1-3 of 3
Claire C. Sharpe
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Effect of Crizanlizumab and Standard of Care (SoC) Versus Standard of Care Alone on Renal Function in Patients with Chronic Kidney Disease Due to Sickle Cell Nephropathy (STEADFAST)

Santosh L. Saraf, Kenneth I. Ataga, Vimal K. Derebail, Claire C. Sharpe, Adlette Inati, Jeffrey D. Lebensburger, Laurie DeBonnett, Yifan Zhang, Pablo Bartolucci
Journal: Blood
Blood (2021) 138 (Supplement 1): 3096.
https://doi.org/10.1182/blood-2021-149849
Published: 2021
Journal Articles

The Effect of Crizanlizumab Plus Standard of Care (SoC) Versus Soc Alone on Renal Function in Patients with Sickle Cell Disease and Chronic Kidney Disease: A Randomized, Multicenter, Open-Label, Phase II Study (STEADFAST)

Kenneth I. Ataga, MD, Santosh L. Saraf, MD, Vimal K. Derebail, MD, Claire C. Sharpe, Adlette Inati, MD, Jeffrey D. Lebensburger, DO, MSPH, Laurie DeBonnett, MD, Shirong Zhang, Pablo Bartolucci, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1018.
https://doi.org/10.1182/blood-2019-124823
Published: 2019
Journal Articles

How I treat renal complications in sickle cell disease

Claire C. Sharpe, Swee Lay Thein
Journal: Blood
Blood (2014) 123 (24): 3720–3726.
https://doi.org/10.1182/blood-2014-02-557439
Published: 2014